74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Gossamer Bio Inc
Closed
SectorHealthcare
0.96 9.09
Overview
Share price change
24h
Min
0.88
Max
0.99
Income | -2.2M -33M |
|---|---|
Sales | -101K 9.4M |
EPS | -0.15 |
Profit margin | -352.159 |
Employees | 144 |
EBITDA | -3.5M -32M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +883.15% upside |
Next Earnings | 5 May 2025 |
|---|
Market Cap | -89M 185M |
|---|---|
Previous open | -8.13 |
Previous close | 0.96 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Gossamer Bio Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Gossamer Bio Inc Forecast
Price Target
By TipRanks
883.15% upside
12 Months Forecast
Average 8.75 USD 883.15%
High 15 USD
Low 4 USD
Based on 4 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
